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WE have examined the effects of a PAF receptor antagon-
ist, WEB 2170, on several indices of acute and chronic
airway inflammation and associated changes in lung func-
tion in a primate model of allergic asthma. A single oral
administrationWEB 2170 provided dose related inhibition
of the release of leukotriene C (LTC4) and prostaglandin
D2 (PGD2) recovered and quantified in bronchoalveolar
lavage (BAL) fluid obtained during the acute phase re-
sponse to inhaled antigen. In addition, oral WEB 2170
treatment in dual responder primates blocked the acute
influx of neutrophils into the airways as well as the
associated late-phase airway obstruction occurring 6 h
after antigen inhalation. In contrast, a multiple dosing
regime with WEB 2170 (once a day for 7 consecutive days)
failed to reduce the chronic airway inflammation (eosi-
nophilic) and associated airway hyperresponsiveness to
inhaled methacholine that is characteristic of dual
responder monkeys. Thus, we conclude that the gen-
eration ofPAF following antigen inhalation contributes to
the development of lipid mediators, acute airway
inflammation and associated late-phase airway obstruction
in dual responder primates; however, PAF does not play
a significant role in the maintenance of chronic airway
inflammation and associated airway hyperresponsiveness
in this primate model.
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Introduction
Platelet activating factor (PAF) is a naturally
occurring phospholipid with potent biological
actions that mimic the pathophysiology of asthma.
In the lung PAF mediates a wide range of effects
including bronchoconstriction,
2 mucus hypersecre-
tion, increases in vascular permeability,
4 chemo-
taxis of pro-inflammatory cells and increases in
bronchial responsiveness.
6 In addition to its direct
effects in the lung, PAF may also act indirectly by
inducing arachidonic acid metabolism resulting in
the formation of other lipid mediators that also have
potent bronchoconstrictor and pro-inflammatory
effects in the lungs.
7 Recent studies suggest that
PAF binds to specific receptors located on the
surface of a variety of cells and mediates its
biological effects via activation of a G protein,
phosphoinositide metabolism and subsequent in-
creases in intracellular calcium levels. The presence
of PAF receptors lends itself to pharmacological
intervention with selective receptor antagonists.
The hetrazepine WEB 2170 (bepafant) is a
recently synthesized and characterized selective
PAF receptor antagonist that has potent activity
inhibiting PAF induced responses in a variety of in
vitro and in vivo systems. As such, WEB 2170 is a
potential therapeutic agent that may be useful in the
treatment of asthma and other related inflammatory
diseases. We have previously reported that
late-phase responder monkeys have a persistent,
baseline airway eosinophilia and airway hyperre-
sponsiveness prior to antigen inhalation.
1 Follow-
ing inhalation challenge, these monkeys have an
immediate (acute) and late-phase airway response
that is associated with a large, transient influx of
neutrophils into the airways superimposed on the
baseline chronic airway eosinophilia. Thus, this
model enables one to examine the effects of
treatment on both acute and chronic airway
inflammation and respective changes in airway
function.
The purpose of this study was to examine the
effects of WEB 2170 on antigen induced acute
airway inflammation and associated changes in
airway function. In addition, we also examined its
eflqcacy in reducing chronic airway inflammation
and airway hyperresponsiveness, characteristic of
dual responder monkeys.
Methods
Animals" Animals used in this study were wild
caught, adult male cynomolgus monkeys (Macaca
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fascicularis) weighing 3.5-7.5 kg and demonstrating
a naturally occurring respiratory hypersensitivity to
Ascaris suum extract. Monkeys were housed
individually in specially designed open mesh cages,
provided food twice a day and water ad libitum. All
protocols used in this study were approved by the
Animal Care and Use Committee at Boehringer
Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
General protocol: For each study, monkeys were
anaesthetized with an intramuscular injection of
ketamine hydrochloride (4 mg/kg) and xylazine
(1 mg/kg), intubated with a cuffed endotracheal
tube (5.5 internal diameter) and seated in an upright
position in a specially designed support chair.
Ketamine (4 mg/kg, i.m.) was used to supplement
anaesthesia as needed.
Acute airway inJtammation and late-phase responses: Test
compound or vehicle were administered by gavage
approximately 1 h before antigen challenge. Base-
line respiratory system resistance (Rrs) was
monitored over a 15 min time period after which
antigen inhalation challenge was administered.
Following antigen challenge Rrs was monitored for
10 min (peak immediate response) after which the
animal was removed from the chair, placed in the
supine position and bronchoalveolar lavage (BAL)
was performed with a pediatric bronchoscope. The
measurement of lipid mediators in BAL fluid
recovered after antigen inhalation was determined
as previously described.
11 Following BAL, each
animal was allowed to recover from anaesthesia and
returned to their cage. To monitor the late-phase
response, each animal was re-anaesthetized with the
ketamine/xylazine mixture, intubated, seated in the
support chair and Rrs was monitored over a 15 min
time period. Rrs measurements were recorded at 4,
6, 8, 10 and 24 h post antigen inhalation. In order
to examine antigen induced changes in airway
cellular composition and BAL mediators, BAL was
performed 6 h after antigen challenge on the
opposite lung that was lavaged during the
immediate response. The results of drug treatment
studies were compared to bracketing control studies
in each animal. Experiments were separated by a
minimum of 2 weeks. Animals were fasted for
approximately 18 h prior to use.
Chronic airway inflammation and airway hyperresponsiveness:
In a separate series of studies, the effects of a
multiple dosing regime of WEB 2170 on chronic
airway inflammation and hyperresponsiveness was
examined. On study day 0, animals were anaesthe-
tized (ketamine/xylazine mixture) and airway
responsiveness was evaluated by performing an
inhaled methacholine concentration response de-
termination. Following this procedure, airway
cellular composition was assessed by BAL. On
study day 1, each animal received either vehicle or
WEB 2170 (10mg/kg, p.o.) each day for 7
consecutive days (cross over study design). On
study day 7, airway responsiveness to inhaled
methacholine was evaluated and airway cellular
composition was assessed by performing BAL on
the opposite lung lavaged on day 0 of the study.
Aerosol delivery system and inhalation challange: Aerosol
inhalation challenges were administered by com-
pressed air nebulization and intermittent positive
pressure breathing with a Bird Mark 7A respirator
and micronebulizer (Bird Corporation, model
8158). For antigen inhalation, each challenge
consisted of 15 breaths per min (maximum
inspiratory pressure of 20 cm H20 for 2 min.
A scaris suum extract was diluted with phosphate
buffered saline (PBS, pH 7.4) to the appropriate
concentration for each animal (dose required to
cause a 200-300% increase in Rrs). Antigen
challenges were separated by a minimum of 14 days
for each animal. For inhaled methacholine chal-
lenges, each challenge consisted of 15 breaths per
min for I min. A vehicle (phosphate buffered saline)
inhalation was performed prior to the first dose of
methacholine.
Measurement of respiratory system resistance (Rrs) Respir-
atory system impedance (Zrs) was measured
by discrete frequency (4-40 Hz in eleven equal
logarithmic steps) sinusoidal forced oscillations
superimposed on tidal breathing as described by
Wegner and co-workers.
*e The mean of the real or
in-phase component of Zrs over the entire
frequency range was then computed to provide a
single value representation of Rrs.
Bronchoalveolar lavage (BAL): BAL was performed by
placing each monkey in the supine position and
guiding a fibre-optic bronchoscope past the carina
and wedging into a fifth to seventh generation
bronchi. A 15 ml aliquot of bicarbonate buffered
saline (pH 7.4, 23C) was infused and gently
aspirated through a channel in the bronchoscope.
Concentration of BAL jquid and measurement of lipid
mediators: Collected BAL fluid samples were
concentrated and lipid mediator content analysed as
previously described.
1 Briefly, collected samples
were centrifuged at 600 x g for 10 min at 4C to
remove cells and particulates, after which the
supernatants were diluted with cold ethanol (1:5
dilution). BAL supernatants were again centrifuged
at 600 x g for 10min to remove residual
precipitate. Samples were then concentrated ap-
proximately five-fold under vacuum after which the
samples could be stored at -70C until analysis
by high pressure liquid chromatography (HPLC)
and radioimmunoassay (RIA).
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Histochemistry: BAL cells were evaluated with the use
of cytocentrifuge preparations stained with Diff-
Quick stain. Differential cell counts were de-
termined by counting 200 cells, and the percentage
of each cell type was recorded. Total BAL cells were
determined with the use of a Coulter Counter.
Statistical anasis: Statistical analysis of the level of
lipid mediators, cell influx into the lungs and
immediate and late-phase responses was performed
using a two-way analysis of variance and Duncan’s
multiple comparison t-test where ap value less than
0.05 was considered statistically significant. The
percent inhibition of mediator release, acute and
late-phase responses were calculated using the mean
value of the two bracketing control studies
performed for each dose of WEB 2170 tested.
Results
Antigen induced lipid mediator release: The effects of
antigen inhalation during control (vehicle) and
WEB 2170 treatment studies on the level of BAL
LTC4 and PGD2 are shown in Table 1. Prior to
antigen inhalation LTC4 and PGD2 were present in
concentrated BAL fluid but at very low levels close
to the detectable limits of the RIA. Antigen
challenge resulted in a significant increase in BAL
LTC4 and PGD2 recovered in BAL fluid 20 min
post challenge. Pretreatment with WEB 2170
provided a dose related inhibition of antigen
induced increases in BAL LTC4 and PGD2.
Acute airway inflammation and late-phase obstruction:
Antigen inhalation caused an acute bronchocon-
striction, usually peaking 5 to 10 min post-challenge
and a late-phase response that peaked 6 to 8 h
post-challenge and resolved by 24 h. WEB 2170
treatment did not significantly reduce the peak acute
bronchoconstriction (0-10 rain) but did inhibit the
late-phase response in a dose related manner (Fig.
1).
Airway cellular composition before and after
antigen inhalation is shown in Table 2. Prior to
antigen inhalation, there were a large numbers of
Table 1. Mediators recovered in monkey BAL fluid
Challenge i-LTC4 (ng) i-PGD2 (ng)
PBS 2 + 2 +
Ascaris 45 + 9 32 + 7
+ WEB 2170 (0.3 mg/kg) 41 _+ 6 28 4- 16
(1 mg/kg) 32 4- 12 16 4- 13
(3 mg/kg) 21 4- 8* 16 4- 8*
(10 mg/kg) 17 4- 10" 15 4- 9*
(30 mg/kg) 17 4- 8* 13 4- 6*
Levels of i-LTC4 and i-PGD2 expressed as the total amount
recovered in BAL fluid. *p _< 0.05. Data are the mean 4- SEM.
Control Response
WEEF2170.. treated_
3 10 30
Dose
mg/kg, p.o.
Control Response
WEB-2170 Treated
3 10 30
(n=4) (n--5) = b=4)
Dose
mg/kg, p.o.
FIG. 1. (A) Effects of WEB 2170 treatment on the peak percent increase
in Rrs during the immediate response to inhaled antigen. WEB 2170 (1 h
prior to challenge) had no effect on the immediate response. (B) Effects
of WEB 2170 treatment on the peak percentage increase in Rrs during
the late-phase response. WEB 2170 significantly reduced the late-phase
response at 3, 10 and 30 mg/kg doses. *Indicates statistical significance
(p < 0.05).
eosinophils and very small numbers of neutrophils
recovered by BAL. Antigen inhalation resulted in
a large influx of neutrophils into the airways that
was temporally associated (6 h) with the occurrence
of the late-phase airway obstruction. WEB 2170 at
doses of 10 and 30 mg/kg significantly inhibited the
late-phase associated influx of neutrophils into the
airways (Table 3).
Chronic airway inflammation and airway hyperresponsiveness:
The effect of multiple doses of WEB 2170 on the
baseline airway eosinophilia is shown in Fig. 2A.
WEB 2170 treatment did not significantly reduce
the number of eosinophils recovered by BAL on
day 7 compared to day 0 of the study. Similarly,
WEB 2170 treatment had no effect on the airway
hyperresponsiveness to inhaled methacholine (Fig.
2B).
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Table 2. Airway cellular composition
Time % Macro % Lymph % Neut % Eos Total cells x 105/ml)
Before antigen 39 _+ 9 5 _+ 8 _+ 3 48 _+ 6 4.56 _+ 0.63
(178) (22.8) (36.5) (219)
6 h post-antigen 22 +_ 7 4 _+ 2 59 _+ 8* 15 _+ 5 7.93 _+ 0.89*
(175) (31.7) (468)* (119)
*p_< 0.05.
Figures in parentheses are the number of cells x 103/ml BAL. Data are the mean -I- SEM, n 12.
Table 3. Effects of WEB 2170 on neutrophil influx
Compound Dose n
(mg/kg)
Neutrophil influx (x 103/ml)
Control Drug treatment % Inhibition
WEB 2170 1.0 4 235 + 27 303 + 69 0
3.0 5 354 _+ 38 192 _+ 52 45
10.0 6 323 + 48 95 + 61 71
30.0 4 390 + 68 129 + 36 67
Data are mean +_ SEM. Control values represent data from bracketing control
studies.
*p_< 0.05.
A I 400
300
200 -4
00 -
0
Day 1 Day 7
Day 1 Day 7
FIG. 2. (A) Effects of WEB 2170 treatment on the number of eosinophils
recovered by BAL. Multiple dosing (10 mg/kg/day, p.o.) of WEB 2170
had no effect on the number of resident eosinophils in the airways of
dual responder primates. Data are the mean -t- SEM, n 6. (B) Airway
responsiveness to inhaled methacholine prior to multiple dosing with
WEB 2170 (day and after (day 7). WEB 2170 treatment showed no
improvement in airway hyperresponsiveness to inhaled methacholine.
Individual data for each animal are shown as well as the mean ___
SEM
for the group.
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Discussion
PAF is a pro-inflammatory mediator that has potent
eects in the airways that mimic the pathophysio-
logy of asthma. Recent studies demonstrate that
PAF mediates it potent biological effects by binding
to specific receptors on the cell surface.
13WEB 2170
is a potent PAF receptor antagonist that blocks the
effects of PAF in vitro and in vivo.
9 In the current
study, we have examined the effects of WEB 2170
in a primate model of acute and chronic airway
inflammation and associated changes in lung
function. The results of this study demonstrate that
WEB 2170 inhibits the production and release of
arachidonic acid metabolites in the lung during the
immediate response to inhaled antigen (0-10 min)
as well as the late-phase airway obstruction. WEB
2170 also significantly inhibited the acute neu-
trophilic influx into the lungs that is associated with
late-phase airway obstruction. In contrast, WEB
2170 had no effect on the baseline airway
eosinophilia nor did it reduce the airway hyperre-
sponsiveness to inhaled methacholine characteristic
of dual responder monkeys.
Previous studies have demonstrated that PAF
stimulates the generation of leukotrienes from
human neutrophils at concentrations as low as
10-10 M.8 Furthermore, PAF stimulates leukotriene
synthesis in vivo in several species including the cat
and rat. 14’1s Our study demonstrates that a PAF
receptor antagonist inhibits the production and
release of arachidonic acid metabolites (LTC4 and
PGD2) in the lung following antigen challenge.
Although we significantly reduced the production
of arachidonic acid metabolites, we did not see aPAF, acute and chronic airway inflammation
reduction in the peak increase in Rrs during the
immediate response to inhaled antigen. This
observation is consistent with the results of a
previous study in which we demonstrated that lipid
mediators contribute to the duration of the
immediate response and not to the peak broncho-
constriction.
11 In the present study we did not
monitor the duration of the immediate response to
antigen but focused on the measurement of lipid
mediators in BAL fluid. While the cellular sources
of PAF, LTC4 and PGD2 were not addressed in this
study, other studies have demonstrated that
activated eosinophils generate large amounts of
PAF and leukotrienes. 16’7 We have previously
reported that late-phase responder monkeys have
higher numbers of eosinophils prior to antigen
challenge compared to single responder monkeys.
1
The late-phase responder monkeys utilized in this
study had high levels of eosinophils (approximately
50% of the airway cells) prior to antigen challenge.
Thus, the eosinophil may be an important source
of potent bronchoactive arachidonic acid metabo-
lites that may contribute to the occurrence of a
late-phase response following antigen inhalation.
Other cells, including mast cells and macrophages,
may also contribute to lipid mediator production in
the lung and may also be affected by WEB 2170.
In sensitized guinea-pigs WEB 2170 in combina-
tion with an antihistamine blocks antigen induced
acute airway constriction suggesting that the
synthesis ofPAF contributes to airway narrowing.
18
Other studies have suggested that PAF may mediate
changes in pulmonary function by causing the
synthesis of other bronchoactive compounds. For
example, Abraham and co-workers have demon-
strated that WEB 2086 (an analogue ofWEB 2170)
inhibits antigen induced late-phase bronchocon-
striction responses in sheep.
9 PAF induced
bronchoconstriction was blocked byWEB 2086 and
by a leukotriene receptor antagonist while in-
domethacin and chlorpheniramine had no effect.
Furthermore, aerosolized LTD4 induced broncho-
constriction was not blocked by WEB 2086, thus
suggesting that PAF induced bronchoconstriction
occurs via the generation of leukotrienes. In this
study, it was hypothesized that WEB 2086 blocked
the late-phase response by inhibiting the production
and release of leukotrienes since leukotriene
receptor antagonists and leukotriene synthesis
inhibitors show similar efficacy.
2 Our study extends
these observations and provides direct evidence of
WEB 2170 mediated leukotriene synthesis inhibi-
tion immediately following antigen challenge as
well as the dose dependent inhibition of the
late-phase airway obstruction. Our results with
WEB 2170 are similar to what we have observed
with a selective 5-1ipoxygenase inhibitor.
2 Thus,
our results with WEB 2170 and a leukotriene
synthesis inhibitor are consistent with the observa-
tions of Abraham and associates.
9
In the primate, the late-phase obstruction
response is chronologically associated with a
transient influx of neutrophils into the airways. We
have recently demonstrated with the use of
monoclonal antibodies against cellular adhesion
proteins that inhibiting the influx of neutrophils
after antigen challenge will block the occurrence of
the late-phase obstruction.
22 These data suggest that
the recruitment and infiltration of neutrophils into
the lungs is necessary for the development of the
late-phase response. Attempts to consistently
measure lipid mediators in BAL fluid during the
late-phase response have been unsuccessful. This
could reflect the limitations of our assay methods
(BAL) or may suggest the involvement of other
mechanisms and/or mediators in the late-phase
airway obstruction. In the present study, WEB 2170
inhibited the influx of neutrophils into the airways
and significantly reduced the late-phase response.
The mechanism by which WEB 2170 inhibits cell
influx and late-phase responses is not known. PAF
is a potent chemotactic agent for neutrophils and
therefore the direct antagonism of the PAF receptor
by WEB 2170 may be involved. In addition,
leukotriene 84 (LTB4) is a potent chemotactic agent
for neutrophils and may also be involved in cell
recruitment into the lungs after antigen challenge.
While in our study we have not measured LTB4
directly, it may be that in addition to inhibiting
LTC4 and PGD2 production and release during the
immediate response, WEB 2170 may be inhibiting
LTB4 production and thereby inhibiting neutrophil
influx. Similar results on antigen induced cellular
infiltrates were reported by Soler and colleagues
23
in studies with allergic sheep. In these studies,
pretreatment with WEB 2086 (before antigen
challenge) significantly reduced the influx of
neutrophils into the airways after antigen challenge,
suggesting that PAF is generated during the
immediate response and mediating the development
of airway inflammation.
Our study is the first to demonstrate that a PAF
receptor antagonist does not reduce chronic airway
inflammation and airway hyperresponsiveness. A 7
day dosing regime of WEB 2170 had no effect on
the chronic airway eosinophilia and hyperrespon-
siveness to inhaled methacholine in dual responder
monkeys. Several possibilities exist as to why we
observed no effect on chronic airway inflammation
and hyperresponsiveness. It is possible that a 7 day
dosing treatment is not a sufficient enough time to
reduce the chronic airway inflammation present in
dual responder monkeys. However, recently we
demonstrated that a 7 day dosing regime with
dexamethasone (0.2 mg/kg, i.m.) significantly re-
duced the chronic airway inflammation and airway
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hyperresponsiveness which would argue against
this possibility.
24 Secondly, it may be that the dose
of WEB 2170 and the dosing regimen selected for
this study was inappropriate. The dose was selected
based on efficacy in antigen induced mediator
release and inhibition of the late-phase response. It
may be that far higher doses and more frequent
dosing (i.e., b.i.d.) are needed to significantly reduce
chronic airway inflammation. On the other hand, it
could be that these high doses may result in an
up-regulation of PAF receptors. Since the duration
of WEB 2170 is approximately 10-12 h after oral
dosing, it is possible that our lack of efficacy in
reducing chronic inflammation is a reflection of a
rebound phenomenon. This could result from the
kinetics of receptors being occupied, resulting in
up-regulation occurring at a time when no
circulating levels of WEB 2170 were present.
Our findings could have profound implications
to the clinical efficacy of PAF receptor antagonists
in asthma, a disease with a recently recognized
important chronic inflammatory component. In
fact, the existing clinical data so far does not
support a rote for PAF in chronic asthma. Several
studies have failed to show inhibition of antigen
induced acute and late-phase reactions with PAF
antagonists.
25-27 In addition, results from a recent
phase 11 steroid sparing study in chronic asthma
indicate that WEB 2086 has no steroid sparing
eects (S. T. Holgate, personal communication).
In summary, we have demonstrated that
pretreatment with a specific PAF receptor antagon-
ist, WEB 2170, effectively reduces acute airway
inflammation and associated changes in lung
function. WEB 2170 treatment inhibited the release
of arachidonic acid metabolites in the lung
produced during the immediate response to inhaled
antigen. Furthermore, WEB 2170 blocked the acute
infiltration of neutrophils into the airways and the
occurrence of a late-phase airway obstruction.
However, WEB 2170 failed to reduce the chronic
baseline airway eosinophilia and airway hyperre-
sponsiveness characteristic of dual responder
monkeys. These results raise serious questions to
the possibility of PAF receptor antagonists as a
novel therapeutic approach to the treatment of
bronchial asthma.
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